New Zealand - engelsk - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - remifentanil hydrochloride 1.097mg equivalent to 1 mg remifentanil;   - powder for injection - 1 mg - active: remifentanil hydrochloride 1.097mg equivalent to 1 mg remifentanil   excipient: glycine hydrochloric acid - remifentanil-aft is indicated as an analgesic agent: · for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery · for the continuation of analgesia in the immediate post-operative period during transition to longer acting analgesia · for the provision of analgesia and sedation in mechanically ventilated intensive care patients.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - remifentanil hydrochloride 2.194mg equivalent to 2 mg remifentanil;   - powder for injection - 2 mg - active: remifentanil hydrochloride 2.194mg equivalent to 2 mg remifentanil   excipient: glycine hydrochloric acid - remifentanil-aft is indicated as an analgesic agent: · for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery · for the continuation of analgesia in the immediate post-operative period during transition to longer acting analgesia · for the provision of analgesia and sedation in mechanically ventilated intensive care patients.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - remifentanil hydrochloride 5.485mg equivalent to 5 mg remifentanil;   - powder for injection - 5 mg - active: remifentanil hydrochloride 5.485mg equivalent to 5 mg remifentanil   excipient: glycine hydrochloric acid - remifentanil-aft is indicated as an analgesic agent: · for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery · for the continuation of analgesia in the immediate post-operative period during transition to longer acting analgesia · for the provision of analgesia and sedation in mechanically ventilated intensive care patients.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - flucloxacillin sodium monohydrate 272.6mg equivalent to flucloxacillin 250 mg;   - capsule - 250 mg - active: flucloxacillin sodium monohydrate 272.6mg equivalent to flucloxacillin 250 mg   excipient: colloidal silicon dioxide gelatin magnesium stearate

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - flucloxacillin sodium monohydrate 545.3mg equivalent to flucloxacillin 500 mg;   - capsule - 500 mg - active: flucloxacillin sodium monohydrate 545.3mg equivalent to flucloxacillin 500 mg   excipient: colloidal silicon dioxide gelatin magnesium stearate

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - flucloxacillin sodium monohydrate 27.2 mg/ml equivalent to flucloxacillin 25 mg/ml;  ; flucloxacillin sodium monohydrate 28.63 mg/ml equivalent to flucloxacillin 25 mg/ml - powder for syrup - 125 mg/5ml - active: flucloxacillin sodium monohydrate 27.2 mg/ml equivalent to flucloxacillin 25 mg/ml   excipient: ammonium glycyrrhizinate disodium edetate dihydrate erythrosine menthol flavour 17410157 pineapple flavour 17410011 saccharin sodium sodium benzoate sodium citrate dihydrate sucrose active: flucloxacillin sodium monohydrate 28.63 mg/ml equivalent to flucloxacillin 25 mg/ml excipient: citric acid monohydrate colloidal silicon dioxide disodium edetate dihydrate lemon flavour 17.41.0212 menthol flavour 17410157 saccharin sodium sodium benzoate sodium citrate sorbitol strawberry flavour 17.43.2172 xanthan gum - the treatment of infections due to gram-positive organisms, including infections caused by ?-lactamase producing staphylococci

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - flucloxacillin sodium monohydrate 54.4 mg/ml equivalent to flucloxacillin 50 mg/ml;  ; flucloxacillin sodium monohydrate 57.26 mg/ml equivalent to flucloxacillin 50 mg/ml - powder for syrup - 250 mg/5ml - active: flucloxacillin sodium monohydrate 54.4 mg/ml equivalent to flucloxacillin 50 mg/ml   excipient: ammonium glycyrrhizinate disodium edetate dihydrate erythrosine menthol flavour 17410157 pineapple flavour 17410011 saccharin sodium sodium benzoate sodium citrate dihydrate sucrose active: flucloxacillin sodium monohydrate 57.26 mg/ml equivalent to flucloxacillin 50 mg/ml excipient: citric acid monohydrate colloidal silicon dioxide disodium edetate dihydrate lemon flavour 17.41.0212 menthol flavour 17410157 saccharin sodium sodium benzoate sodium citrate sorbitol strawberry flavour 17.43.2172 xanthan gum - the treatment of infections due to gram-positive organisms, including infections caused by ?-lactamase producing staphylococci

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - probenecid 500mg;  ;  ;  ;  ; probenecid 500mg; probenecid 500mg - film coated tablet - 500 mg - active: probenecid 500mg         excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry clear ys-1-7006 opadry yellow ys-1-2063 povidone sodium starch glycolate stearic acid active: probenecid 500mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry clear ys-1-7006 opadry yellow ys-1-2063 povidone sodium starch glycolate stearic acid active: probenecid 500mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry clear ys-1-7006 opadry yellow ys-1-2063 povidone sodium starch glycolate stearic acid - · probenecid is a uricosuric agent for the treatment of hyperuricaemia in all stages of gout and gouty arthritis except a presenting acute attack. asymptomatic hyperuricaemia seems to occur in a significant percentage of relatives of gouty patients. probenecid may be given prophylactically to these people to forestall gouty attacks and urate deposition in tissues. by virtue of its effective uricosuric activity, probenecid may be used to control the hyperuricaemia induced or aggravated by many diuretics employed for the treatment of oedema and hypertension (e.g. thiazides and similar diuretics).

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - meropenem trihydrate 1140mg equivalent to meropenem 1000mg;   - powder for injection - 1000 mg - active: meropenem trihydrate 1140mg equivalent to meropenem 1000mg   excipient: sodium carbonate - meropenem-aft is indicated for treatment, in adults and children, of the following infections caused by multiple susceptible bacteria and as empiric therapy prior to the identification of the causative organisms: · lower respiratory tract infections · urinary tract infections, including complicated infections · intra-abdominal infections · gynaecological infections, including postpartum infections · skin and skin structure infections · meningitis · septicaemia · empiric treatment, including initial monotherapy, for presumed bacterial infections in host-compromised, neutropenic patients because of its broad spectrum of bactericidal activity against gram positive and gram-negative aerobic and anaerobic bacteria, meropenem is effective for the treatment of polymicrobial infections.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - meropenem trihydrate 570mg equivalent to meropenem 500mg;   - powder for injection - 500 mg - active: meropenem trihydrate 570mg equivalent to meropenem 500mg   excipient: sodium carbonate - meropenem-aft is indicated for treatment, in adults and children, of the following infections caused by multiple susceptible bacteria and as empiric therapy prior to the identification of the causative organisms: · lower respiratory tract infections · urinary tract infections, including complicated infections · intra-abdominal infections · gynaecological infections, including postpartum infections · skin and skin structure infections · meningitis · septicaemia · empiric treatment, including initial monotherapy, for presumed bacterial infections in host-compromised, neutropenic patients because of its broad spectrum of bactericidal activity against gram positive and gram-negative aerobic and anaerobic bacteria, meropenem is effective for the treatment of polymicrobial infections.